ALLR · Allarity Therapeutics, Inc.

Allarity Therapeutics demonstrated significant operational progress and financial discipline in fiscal year 2025. The company achieved a 55% reduction in net loss, narrowing to $11.2 million from $25.1 million in the prior year. This improvement was primarily driven by a $5.1 million decrease in General and Administrative expenses, which fell to $6.3 million, reflecting management's focus on cost discipline. Research and Development expenses remained relatively stable, increasing slightly to $6.6 million as the company advanced its clinical programs. The company also generated its first revenue of $320 thousand from the commercial licensing of its DRP® companion diagnostic platform and related laboratory services.

Operationally, the company secured FDA Fast Track designation for stenoparib in advanced ovarian cancer, a critical milestone that enables more frequent regulatory engagement and potential accelerated approval pathways. Clinical data continues to show durable benefit, with some patients on therapy for nearly 30 months. A new Phase 2 protocol was implemented to optimize dosing and refine patient selection. Additionally, Allarity expanded its development pipeline into small cell lung cancer through a VA-funded Phase 2 combination study with temozolomide.

The financial position was substantially strengthened post year-end with a $20 million non-convertible debt financing closed in March 2026. Combined with the year-end cash balance of $14.7 million, management indicates this provides runway into mid-2028. Total liabilities were reduced by $2.5 million to $8.4 million at year-end. Leadership changes included the appointment of Jeff Ervin as CFO and Jesper Høiland to the Board of Directors, bolstering financial and strategic governance expertise.